
    
      This is a single-center, open-label, randomized, 5-period, 5-sequence study of the
      pharmacokinetics of a new formulation of deferiprone, extended release tablets, in twenty
      healthy volunteers. In each study period, blood samples for pharmacokinetics assessment will
      be collected pre-dose and over 24 hours post-dose. Safety will be assessed throughout the
      study.
    
  